The outlook of companies tied to flagship drugs like Viagra presents a complex investment scenario . While the initial surge of copyright, fueled by Viagra's remarkable popularity, generated substantial returns, the patent expiration in key regions has introduced considerable uncertainty . Investors are now facing the effect of generic competition